According to Zhitong Finance App News, Huakang Co., Ltd. (605077.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 2,481 billion yuan, an increase of 32.98%; net profit attributable to shareholders of listed companies was 41.96 million yuan, a year-on-year decrease of 68.61%; after deducting non-net profit of 33.08 million yuan, a year-on-year decrease of 72.78%; and basic earnings per share of 0.14 yuan.

During the reporting period, the company's net profit attributable to shareholders of listed companies decreased by 68.61% year-on-year, mainly because Zhoushan Huakang Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was put into operation on a large scale from the second quarter of 2025, and production capacity continued to be released during this period. In order to quickly seize the market, the company adjusted its market expansion strategy for liquid products. The sales share of low-margin liquid products increased, and the overall comprehensive gross margin declined year-on-year due to changes in the product sales structure; at the same time, interest expenses on convertible bonds continued to be calculated in the current period, compounded by fluctuations in foreign exchange rates to jointly drive up current financial expenses. The combination of the above factors led to a year-on-year decline in the company's business performance for the first half year of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.